Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 13/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601704 | 0.89 | PPARG (0.51) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL7663350 | 0.86 | PPARG (0.53) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6604693 | 0.86 | PPARG (0.50) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6605913 | 0.84 | PPARG (0.50) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6602967 | 0.82 | FFAR1 (0.49) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6602049 | 0.80 | FFAR1 (0.49) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6602225 | 0.78 | PPARG (0.52) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6602078 | 0.77 | FFAR1 (0.56) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6600814 | 0.77 | FFAR1 (0.49) | FFAR1PPARGPPARAMEN1ALDH1A1 | |
| SCHEMBL6601560 | 0.76 | PPARG (0.52) | FFAR1PPARGPPARAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036075-B1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | REDDYS LAB LTD DR (IN) | 2004-06-23 | — | — | EP | claimed |
| EP-1036075-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-09-20 | — | — | EP | claimed |
| US-6030973-A | TYPE II DIABETES (NON-INSULIN-DEPENDENT-DIABETES MELLITUS) POTENTIATION; EFFICIENCY; SIDE EFFECT REDUCTION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-02-29 | — | — | US | claimed |
| WO-1998045291-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-10-15 | — | — | WO | claimed |
| EP-1036075-B1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | REDDYS LAB LTD DR (IN) | 2004-06-23 | — | — | EP | disclosed |
| US-6313113-B1 | AZOLIDINEDIONE DERIVATIVES, ANALOGUES, TAUTOMERIC FORMS, STEREOISOMERS, POLYMORPHS, SALTS AND SOLVATES; TREATING NON-INSULIN-DEPENDENT DIABETES MELLITUS | REDDY-CHEMINOR, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1036075-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-09-20 | — | — | EP | disclosed |
| US-6030973-A | TYPE II DIABETES (NON-INSULIN-DEPENDENT-DIABETES MELLITUS) POTENTIATION; EFFICIENCY; SIDE EFFECT REDUCTION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-02-29 | — | — | US | disclosed |
| WO-1998045291-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-10-15 | — | — | WO | disclosed |